Here are the latest quarterly results of PANACEA BIOTECH. For more details, see the PANACEA BIOTECH financial fact sheet and PANACEA BIOTECH share price and chart. For a sector overview, read our pharmaceuticals sector report.
No. of Mths Qtr. Ending |
3
Jun-20* |
3
Sep-20* |
3
Dec-20* |
3
Mar-21* |
3
Jun-21* |
3
Sep-21* |
3
Dec-21* |
3
Mar-22* |
8-Qtr Chart Click to enlarge |
|
---|---|---|---|---|---|---|---|---|---|---|
Net Sales | Rs m | 1,328 | 1,820 | 1,418 | 1,683 | 1,325 | 2,322 | 1,559 | 1,407 | |
Other income | Rs m | 12 | 20 | 19 | 49 | 32 | 20 | 17 | 41 | |
Turnover | Rs m | 1,340 | 1,840 | 1,437 | 1,732 | 1,357 | 2,342 | 1,575 | 1,448 | |
Expenses | Rs m | 1,102 | 1,440 | 1,266 | 1,673 | 1,340 | 2,262 | 1,440 | 1,709 | |
Gross profit | Rs m | 225 | 380 | 152 | 9 | -16 | 60 | 119 | 16,460 | |
Depreciation | Rs m | 113 | 114 | 113 | 116 | 111 | 109 | 106 | 112 | |
Interest | Rs m | 452 | 475 | 457 | 469 | 479 | 502 | 521 | 307 | |
Profit before tax | Rs m | -328 | -189 | -400 | -527 | -573 | -530 | -492 | 16,083 | |
Tax | Rs m | 3 | 1 | 0 | 15 | 1 | 0 | 0 | 3,708 | |
Profit after tax | Rs m | -332 | -190 | -400 | -541 | -574 | -530 | -492 | 12,375 | |
Gross profit margin | % | 17.0 | 20.9 | 10.7 | 0.6 | -1.2 | 2.6 | 7.6 | 1,169.6 | |
Effective tax rate | % | -1.0 | -0.5 | -0.1 | -2.8 | -0.1 | 0.0 | -0.1 | 23.1 | |
Net profit margin | % | -25.0 | -10.4 | -28.2 | -32.2 | -43.3 | -22.8 | -31.6 | 879.3 | |
Diluted EPS | Rs | -5.4 | -3.1 | -6.5 | -8.8 | -9.4 | -8.7 | -8.0 | 202.0 | |
Diluted EPS (TTM) | Rs | -31.8 | -23.0 | -26.2 | -23.9 | -27.8 | -33.4 | -34.9 | 176.0 | |
![]() |
After opening the day deep in the red, Indian share markets slowly recovered most of their losses and ended on a flat note.
These companies are likely to benefit the most from Covid-19 vaccines.
It came as a surprise to everyone when Sun Pharma reported a consolidated net loss in Q4 instead of a profit.
Here's why Divi's Lab's stock fell over 10% in two days.
For full year, profit figures stood at Rs 29.6 bn as against Rs 19.8 bn for the previous year, reflecting a growth of 49%.
During Q4, there were many changes to the products forming part of Dr Reddy's generics and proprietary products segments.
More Views on NewsConstant product innovation, latest technology, strong supply chain etc can all help companies enjoy monopoly like fortunes.
This aspect of investing has a very high weightage on your overall returns, but often gets ignored when winning stories are written.
Why this may not be the best time to buy smallcaps.
The good side of a market correction? Investors get consistent compounding stocks at a discount.
These value stocks have the potential to deliver good returns in the long run. Watch out for them.
More